The Glutton Mechanical Aspiration Thrombectomy Device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IVt-PA) or who fail IV t-PA therapy are candidates for treatment.
GluttonTM Mechanical Aspiration Thrombectomy Device is a single lumen, flexible, variable stiffness catheter. The distal segment is steam-shapeable to facilitate vessel selection and also has a hydrophilic coating to aid navigation through the vasculature. A radiopaque marker is located at the distal end of the catheter for visualization under fluoroscopy. The Glutton Aspiration Catheter is designed to remove thrombus from the vasculature using continuous aspiration.
Features &Advantages
1. Structure of coil and braid improves anti-kink performance and easily cross tortuous blood vessels.
2. Structure of coil and braid optimizes pushing force and improves the passing performance, and then quickly reach the lesion site.
3. 0.072 inch ultra-large lumen improves aspirating ability.
4. Distal multi-segment design of gradual hardness provides a stable passability guarantee.
5. The distal segment is steam-shapeable to facilitate vessel selection and aid navigation through the vasculature.
6. Hydrophilic coating at the distal end reduces friction during navigation to reach distal occlusion easily.
Indication For Use
1. The Dredger Revascularization Device (Dredger RD) is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior
circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should start within 6 hours of symptom onset.
2. The Dredger RD is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.
